Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,627 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,360 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04313075 | A Compassionate Use Study of Leronlimab in Breast Cancer | no longer available | — | — | CytoDyn, Inc.INDUSTRY | 0 | Jul 15, 2025 | clinicaltrials |
| NCT03123211 | Expanded Access to Veliparib | no longer available | — | — | AbbVieINDUSTRY | 0 | May 24, 2022 | clinicaltrials |
| NCT02985658 |
| Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer |
| no longer available |
| — |
| — |
| University of WashingtonOTHER |
| 1 |
| Jul 21, 2021 |
| clinicaltrials |
| NCT03554434 | An Expanded Access Program for AM0010 (Pegilodecakin) | no longer available | — | — | Eli Lilly and CompanyINDUSTRY | 0 | Mar 2, 2020 | clinicaltrials |
| NCT01120561 | A Study of Trastuzumab-MCC-DM1 in Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer | no longer available | — | — | Genentech, Inc.INDUSTRY | 1 | Feb 15, 2017 | clinicaltrials |
| NCT01130259 | An Open-Label, Expanded Access Protocol of Iniparib Breast Cancer | no longer available | — | — | SanofiINDUSTRY | 0 | Sep 17, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Jul 15, 2025source: clinicaltrials